Analyst Ratings for [SENS] Senseonics Holdings, Inc.

7/15/25	Initiated	Buy	X
SENS Senseonics TD Cowen
$1.25
6/2/25	Resumed	Buy	X
SENS Senseonics H.C. Wainwright
$1.10
4/10/25	Initiated	Outperform	X
SENS Senseonics Mizuho
$2
7/19/23	Initiated	Underperform	X
SENS Senseonics Jefferies
$0.50
4/1/21	Downgrades	Outperform Mkt Perform	X
SENS Senseonics SVB Leerink
$3
3/5/21	Downgrades	Mkt Perform Underperform	X
SENS Senseonics Raymond James
1/21/21	Downgrades	Buy Neutral	X
SENS Senseonics BTIG Research
1/20/21	Downgrades	Hold Sell	X
SENS Senseonics Craig Hallum
7/5/19	Downgrades	Outperform Mkt Perform	X
SENS Senseonics Raymond James
1/29/19	Initiated	Neutral	X
SENS Senseonics Piper Jaffray
8/24/18	Initiated	Buy	X
SENS Senseonics Dougherty & Company
$6

SENS Senseonics Holdings, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Senseonics Holdings, Inc. is a medical technology company. The Company focuses on the design, development and commercialization of glucose monitoring systems. The Company operates through glucose monitoring systems segment. It offers a continuous glucose monitoring (CGM) system, Eversense, which is designed an implantable CGM system designed to continually measure glucose levels in people with diabetes. The Company's Eversense system consists of components, such as a sensor, which is inserted subcutaneously in the upper arm by a healthcare provider; an external removable smart transmitter that receives, assesses and relays the data from the sensor and also provides vibratory alerts, and a mobile application that receives data from the transmitter and provides real-time glucose readings, alerts and other data on the user's mobile device, such as a smartphone, Apple Watch or tablet.